Search Results - "Morante, E Serramontmany"

5PSQ-070 Pharmaceutical care in an onco-haematological clinical trials unit by García Basas, L, Varon-Galcera, C, Garcia Ortega, P, Serramontmany Morante, E, Gimenez Giner, S, Carreres Prieto, M, Rovira Torres, P, Cidoncha Muñoz, I, Gorgas Torner, MQ

“…Background and ImportanceThe pharmacist’s role in the health care for patients participating in clinical trials (CTs) goes beyond telling them how to take the…”
Get full text

6ER-021 Evaluation of COVID mortality during hospital admission in patients receiving oncological treatment by Serramontmany Morante, E, Cardona-Pascual, I, Garcia Ortega, P, Carreras Soler, M, Gorgas Torner, MQ, Cidoncha Muñoz, I, Felip Font, E

“…Background and importanceCOVID-19 mortality changes depending on patients’ characteristics. The literature describes similar mortality in general COVID-19…”
Get full text

5PSQ-124 The role of the clinical pharmacist in avoiding medication errors in a clinical research onco-haematologic unit by Garcia Ortega, P, Serramontmany Morante, E, Garcia Basas, L, Latorre García, P, Rovira Torres, P, Manos Pujol, L, Cidoncha Muñoz, I, Gorgas Torner, MQ

“…Background and importanceThe complexity in the design and execution of clinical trials has created the need to coordinate a multidisciplinary team in which the…”
Get full text

4CPS-286 Early impact of COVID on the activity of a clinical research oncology pharmacy unit at a tertiary care hospital by Rovira Torres, P, Latorre García, P, Martinez Casanova, J, Esteban Sanchez, C, Serramontmany Morante, E, Garcia Ortega, P, Carreres Prieto, M, Maños Pujol, L, Cidoncha Muñoz, I

“…Background and importanceThe COVID-19 pandemic has impacted notably on clinical care and led to numerous challenges in the conduct of clinical trials (CT)…”
Get full text

4CPS-129 Evaluation of the real infusion time of intravenous immunoglobulin and influential factors in routine clinical practice analysis by Martinez, C Alonso, Morante, E Serramontmany, Izquierdo, A Roig, Ortin, E Lozano, Gomila, M Garau, Sebastia, L Betriu, Ronsano, JB Montoro

“…BackgroundIntravenous immunoglobulin (IVIG) is the standard of care for humoral immunodeficiencies (HID) and several systemic autoimmune diseases. Its chronic…”
Get full text

4CPS-022 Prevalence of potassium, phosphorus and calcium imbalance in very-low-birthweight-preterm infants receiving parenteral nutrition from the first day of life by Teixido, CJ Parramon, Ganda, L Gómez, Palop, B García, Salinas, F Castillo, Palazón, M Linés, Grau, A Blanco, García, M Larrosa, Sebastia, L Betriu, Morante, E Serramontmany, Garcia, S Garcia, Bautista, S Clemente

“…BackgroundEarly aggressive parenteral nutrition (APN), consisting of high protein (2.5–3.5 g/kg/day) and high lipid (2 g/kg/day) administration from birth…”
Get full text